# Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC

> **NCT05993858** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 33 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Neoadjuvant Therapy

## Interventions

- **DRUG:** 3cycles (Toripalimab + cetuximab)
- **PROCEDURE:** Surgery
- **RADIATION:** Radiotherapy or chemoradiotherapy

## Key facts

- **NCT ID:** NCT05993858
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-20
- **Primary completion:** 2025-12-20
- **Final completion:** 2026-12-20
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05993858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05993858, "Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05993858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*